GHK-Cu Side Effects: Potentially Permanent Risks Explained

Has a permanent GHK-Cu side effect ever been reported?

None has been established. The two randomized human trials that come closest to a safety readout did not describe lasting harm, but they also did not report adverse-event rates.

In the first, 13 patients completed a study in which skin around the mouth was resurfaced with a CO2 laser and patients were randomized to skin care with or without GHK-Cu. Computer analysis and blinded evaluators found no significant difference in how quickly redness resolved. All patients improved in wrinkles and overall skin quality, with no difference between groups. On a patient questionnaire, the GHK-Cu group reported better overall skin quality (P=.04) [1].

In the second, 86 evaluable patients with venous stasis ulcers were randomized to a 0.4% tripeptide copper complex cream, silver sulfadiazine 1%, or an inert vehicle. The copper cream was no different from placebo; silver sulfadiazine reduced ulcer size [2].

Fewer than 100 patients completed these two trials combined, so neither was in a position to detect rare events [1][2].

What does FDA say about injectable GHK-Cu?

FDA's page on bulk substances that may raise significant safety risks lists "GHK-Cu (for injectable routes of administration)" in its table of substances nominated but withdrawn. The agency's stated concern: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations." [4]

For contrast, non-injectable GHK-Cu sits in category 1, the group under evaluation for the pharmacy bulks list, and FDA says it generally does not intend to act against compounders for category 1 substances when the conditions in its guidance are met [7][9]. Injectable GHK-Cu is not in category 1 and does not appear in any category on FDA's current list [7]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether to include GHK-Cu on that list, and no vote has happened yet [7].

Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they reach patients [8].

Copper warnings come from a different product

GHK-Cu is a copper complex: GHK is a tripeptide that binds copper(II), and it is proposed that GHK works as a copper complex [10]. Copper is an essential nutrient, but excess copper ions can generate free radicals and increase oxidative stress [11].

The label for cupric chloride injection is a different product: an intravenous copper additive for total parenteral nutrition. It says copper is primarily eliminated in bile and that excretion is decreased in cholestasis and cirrhosis. It reports hepatic accumulation of copper at autopsy in patients who received long-term parenteral nutrition containing copper above the recommended dose, and says that giving copper to patients with Wilson disease may increase hepatic accumulation and aggravate underlying hepatocellular degeneration [5].

The same label lists hypersensitivity to copper as a contraindication and cites postmarket reports of copper hypersensitivity in women with copper-containing intrauterine devices [5]. Its overdose section describes acute copper toxicity, reported with oral, intravenous or subcutaneous administration, as metallic taste, nausea, vomiting, diarrhea, abdominal pain, neurological signs such as encephalopathy, and multi-organ failure that may be fatal [5].

None of this comes from GHK-Cu studies. GHK-Cu has not been tested in people with Wilson disease, cholestasis or cirrhosis, and a copper reaction of this kind is not a documented effect of GHK-Cu itself.

Topical versus injectable: two different products

Whether a copper peptide product is a cosmetic or a drug depends on its intended use. Cosmetics and cosmetic ingredients other than color additives do not need FDA approval before they are sold, so copper peptide serums and creams reach the market as cosmetics [6]. Claims that a product treats disease or changes the structure or function of the body make it a drug under the law [6]. An injectable GHK-Cu product is not a cosmetic and is not FDA-approved [6].

On the clinical side, a 2026 systematic review covering 2005 to 2026 retained 64 records. Its authors wrote that the human literature remains thin and fragmented, that most randomized trials are small and use facial cosmetic creams, and that microneedle delivery of GHK-Cu has not been tested in a single registered, adequately powered human randomized trial [3].

What is still unknown

Long-term human safety data on GHK-Cu are missing. The laser-resurfacing trial followed patients for 12 weeks, and the venous-ulcer trial reported results for 86 evaluable patients [1][2]. The 2026 review concluded that four decades of laboratory and animal work have not been matched by adequate human trials [3].

What can be said plainly: GHK-Cu has not been shown to cause permanent harm, and it has not been shown to be free of it either. The clearest safety warning aimed at GHK-Cu itself is FDA's immunogenicity concern about compounded injectables.